Paeds · nephrology-urology-fluids-and-electrolytes
Lupus nephritis and systemic disease
Also known as Lupus nephritis · Lupus nephropathy · Childhood-onset lupus nephritis · SLE nephritis · ISN/RPS lupus nephritis classification
Fellowship guide to paediatric lupus nephritis: the six-class ISN/RPS 2003 classification (I minimal mesangial through VI advanced sclerosing), why Class IV diffuse proliferative dominates childhood disease, the immune-complex pathophysiology behind the full-house immunofluorescence pattern, and the induction-maintenance treatment paradigm built on mycophenolate mofetil or low-dose cyclophosphamide with glucocorticoids, treat-to-target proteinuria goals, and hydroxychloroquine for every patient.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- New hypertension, oedema, and foamy or tea-coloured urine in an adolescent girl with malar rash, oral ulcers, or arthralgia
- Active urinary sediment with haematuria, proteinuria, and red cell casts signalling proliferative Class III or IV lupus nephritis
- Nephrotic-range proteinuria without haematuria suggesting pure membranous Class V lupus nephritis
- Rapidly rising creatinine with active sediments and falling complement, demanding urgent renal biopsy and induction therapy
- Rapidly progressive glomerulonephritis with crescents on biopsy carrying a high risk of end-stage kidney disease
- Low C3 and C4 with high-titre anti-dsDNA antibodies confirming active immune-complex disease
- Adolescent with unexplained seizures or psychosis and new renal abnormality indicating neuropsychiatric lupus with nephritis
Life stages
Care settings
Clinical exam formats
Board mappings
- Recognises that renal involvement in childhood SLE is common, serious, and demands prompt biopsy
- Names the six ISN/RPS classes and identifies Class IV as the most severe proliferative pattern
- Initiates urinalysis, complement, and anti-dsDNA in any child with suspected lupus and refers to nephrology
- Justifies induction with mycophenolate mofetil or low-dose cyclophosphamide plus glucocorticoids for proliferative disease
- Applies treat-to-target goals of complete and partial renal response using proteinuria and creatinine
- Manages refractory disease with calcineurin inhibitors, rituximab, or belimumab and coordinates long-term renal and reproductive follow-up
- ISN/RPS six-class classification of lupus nephritis and the clinical significance of each
- Role of immune complex deposition and full-house immunofluorescence in pathophysiology
- Induction and maintenance therapy framework and the importance of hydroxychloroquine
- Recognises a deteriorating adolescent with lupus nephritis and escalates to induction therapy
- Communicates the diagnosis, prognosis, and need for adherence to long-term immunosuppression
- Counsels on gonadal toxicity of cyclophosphamide, contraception, and transition to adult care
- Level 1: Recognition that lupus can affect the kidney and that proteinuria plus haematuria warrants referral
- Level 2: Interpretation of the ISN/RPS classification and initiation of induction therapy with nephrology
- Level 3: Management of refractory disease, treatment toxicity, and coordination of transitional care
- ISN/RPS classification of lupus nephritis with Class IV diffuse proliferative as the dominant severe pattern
- Full-house immunofluorescence and the classical complement pathway in pathogenesis
- Induction and maintenance regimens, treat-to-target goals, and the role of hydroxychloroquine
- Assessment and initial management of an adolescent girl with malar rash, oedema, and active urinary sediment
- Interpretation of renal biopsy and complement studies in suspected lupus nephritis
- Structured explanation of the induction-maintenance paradigm and counselling on cyclophosphamide toxicity
- Recognition and initial evaluation of paediatric lupus nephritis including biopsy indications
- Classification of lupus nephritis and the rationale for immunosuppressive induction
- Mycophenolate-based therapy, treat-to-target monitoring, and hydroxychloroquine for all patients
- Recognition of renal involvement as a major determinant of morbidity in childhood-onset SLE
- Initiation of appropriate investigations and urgent nephrology referral
- Family communication on diagnosis, treatment adherence, and long-term renal surveillance
- Canadian approach to lupus nephritis classification and induction-maintenance therapy
- Use of calcineurin inhibitors and biologic agents in refractory disease
- Long-term renal and reproductive follow-up after immunosuppression
Overview & Definition
A 13-year-old girl who has been losing weight and complaining of swollen fingers presents with puffy eyelids, dark urine, and a blood pressure of 135 over 85. She has oral ulcers and a faint rash across her cheeks. Her urine shows blood and protein, her creatinine is mildly elevated, and her complement C3 and C4 are low. This is lupus nephritis, the renal manifestation of systemic lupus erythematosus, in which autoantibodies form immune complexes that deposit in the glomerulus and trigger inflammation. It is one of the most serious complications of childhood-onset lupus and the single strongest predictor of long-term morbidity and mortality in the disease. [9]
Renal involvement is both more frequent and more severe in children than in adults. Up to 50 to 80 percent of children with systemic lupus erythematosus develop nephritis, compared with roughly 30 to 40 percent of adults, and children are more likely to present with the aggressive proliferative Class III and IV patterns. Most childhood-onset lupus is diagnosed in adolescence, with a striking female predominance driven by oestrogen, and disease onset before puberty tends to be more severe. Because the kidney can be the first or only obviously affected organ, any child with unexplained haematuria, proteinuria, hypertension, or declining renal function needs lupus excluded. [9]
References12ShowHide
- [1]Weening JJ, D'Agati VD, Schwartz MM, et al The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol, 2004.PMID 14747370
- [2]Ginzler EM, Dooley MA, Aranow C, et al Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med, 2005.PMID 16306519
- [3]Appel GB, Contreras G, Dooley MA, et al Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol, 2009.PMID 19369404
- [4]Contreras G, Pardo V, Leclercq B, et al Sequential therapies for proliferative lupus nephritis. N Engl J Med, 2004.PMID 14999109
- [5]Rovin BH, Teng YKO, Ginzler EM, et al Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, 2021.PMID 33971155
- [6]Rovin BH, Furie R, Latinis K, et al Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum, 2012.PMID 22231479
- [7]Fanouriakis A, Kostopoulou M, Cheema K, et al 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis, 2020.PMID 32220834
- [8]Sammaritano LR, Askanase A, Bermas BL, et al 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol, 2025.PMID 40331662
- [9]Smitherman EA, Chahine RA, Beukelman T, et al Childhood-Onset Lupus Nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short-Term Kidney Status and Variation in Care. Arthritis Care Res (Hoboken), 2023.PMID 36775844
- [10]Mina R, von Scheven E, Ardoin SP, et al Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken), 2012.PMID 22162255
- [11]Sundel R, Solomons N, Lisk L Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus, 2012.PMID 22922564
- [12]Hinze CH, Suzuki M, Klein-Gitelman M, et al Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum, 2009.PMID 19714584